Vident Investment Advisory’s BioMarin Pharmaceuticals BMRN Stock Holding History

Vident Investment Advisory’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,307	Closed	-$794K	–	1285
2022 Q1	$794K	Sell	10,307 -456	-4%	-$38.2K	0.02%	786
2021 Q4	$950K	Buy	10,763 +293	+3%	+$24.2K	0.02%	726
2021 Q3	$809K	Sell	10,470 -628	-6%	-$49.5K	0.02%	747
2021 Q2	$926K	Buy	11,098 +320	+3%	+$25.4K	0.03%	675
2021 Q1	$814K	Buy	10,778 +472	+5%	+$38.6K	0.03%	667
2020 Q4	$903K	Buy	10,306 +3,146	+44%	+$249K	0.04%	567
2020 Q3	$545K	Buy	7,160 +1,194	+20%	+$121K	0.03%	643
2020 Q2	$736K	Buy	+5,966	New	+$593K	0.04%	557

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vident Investment Advisory's BMRN Position: Q2 2022 in Review

Vident Investment Advisory sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 10,307 shares — an estimated $794K sold.

Vident Investment Advisory first reported a position in BMRN in Q2 2020 and held it in 8 quarters. The position peaked at $950K in Q4 2021. 542 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

Vident Investment Advisory reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Vident Investment Advisory sold 10,307 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $794K.
Vident Investment Advisory first reported a position in BioMarin Pharmaceuticals in Q2 2020 and held it in 8 quarters.
Vident Investment Advisory's BioMarin Pharmaceuticals position peaked at $950K in Q4 2021.
542 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Vident Investment Advisory's 13F filing for Q2 2022, filed 15 Aug 2022.